| Vol. 4.30 – 14 August, 2020 |
| |
|
|
| Researchers demonstrated that primary mouse and human hepatocytes can undergo pyroptosis upon NLRP3 inflammasome activation with subsequent release of NLRP3 inflammasome proteins that amplified and perpetuated inflammasome-driven fibrogenesis. [Journal of Hepatology] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
|
Scientists investigated a direct role of Yap in constitutive androstane receptor (CAR)‐driven hepatomegaly and hepatocyte proliferation using hepatocyte‐specific Yap‐KO mice. AAV8‐TBG‐CRE vector was injected to Yap‐floxed mice for achieving hepatocyte‐specific Yap deletion followed by TCPOBOP‐treatment. [Hepatology] |
| | Induced hepatocyte-like (iHep) cells were generated from induced pluripotent stem cells integrated with the albumin reporter gene. The therapeutic properties of these iHep cells were investigated after transplantation in fibrotic liver tissues of a mouse model. [Stem Cell Research & Therapy] |
|
|
|
| The 32A9 immunotoxin exhibited specific cytotoxicity to GPC3-positive cancer cells, while 32A9 CAR-T cells efficiently eliminated glypican-3-positive hepatocellular carcinoma cells in vitro. [Journal of Translational Medicine] |
|
|
|
| Mrp2 levels at the plasma membrane of PI3Kγ KO hepatocytes remained unaffected upon PI3K/Akt signaling stimulation. The effect explicitly relied on PI3Kγ’s enzymatic ability, as shown by PI3Kγ kinase-dead mice. [Scientific Reports] |
|
|
|
| Investigators showed that mouse scavenger receptor class B type 1 (SR-B1) was less functional as compared to human SR-B1 during P. berghei infection. They took advantage of this functional difference to investigate the structural determinants of SR-B1 required for infection. [Scientific Reports] |
|
|
|
| Neohesperidin (NHP) elevated hepatic mitochondrial biogenesis and fatty acid oxidation by increasing PGC-1α expression. The activation of AMP-activated protein kinase was involved in NHP induced PGC-1α expression. [FASEB Journal] |
|
|
|
| Scientists revealed a novel mechanism of FBX8 in regulating tumor metastatic dormancy in liver and provided new strategies for the treatment of colorectal cancer metastasis. [Cell Death & Disease] |
|
|
|
| A xenograft tumour assay was used to validate the role of KCNQ1OT1 in vivo. KCNQ1OT1 and S1PR1 were significantly increased, but miR-149 was decreased in hepatocellular carcinoma cells. [Cancer Gene Therapy] |
|
|
|
|
| Scientists propose a new vaccine platform that enhances all three arms of the adaptive immune system to improve tumor‐associated antigens‐based cancer vaccination in hepatocellular carcinoma patients. [Hepatology] |
|
|
|
| Researchers examine recent advances in targeted therapy and discuss the impact this has had on the management of hepatocellular carcinoma (HCC). They also provide an overview of the most important areas of HCC research including novel clinical trials and technical platforms which promise to facilitate substantial progress within the next decade. [Signal Transduction and Targeted Therapy] |
|
|
|
| The authors comprehensively summarize the emerging upstream regulators, downstream substrates, mouse models, clinical relevance, and candidate inhibitors for SIKs, and shed light on SIKs as the potential therapeutic targets for cancer therapies. [Signal Transduction and Targeted Therapy] |
|
|
|
|
| Dicerna Pharmaceuticals, Inc. has announced positive data from its Phase I proof-of-concept trial of RG6346, an investigational candidate for the treatment of chronic hepatitis B virus infection in development in collaboration with Roche. [Dicerna Pharmaceuticals, Inc.] |
|
|
|
| Provectus has announced that they have expanded its sponsored research program with the Cumming School of Medicine of the University of Calgary. The Calgary team will investigate oral dosing of cGMP rose bengal disodium in in vivo murine models for the treatment of refractory adult solid tumors that are high-risk phenotypes, including head and neck, breast, pancreatic, liver, and colorectal. [Provectus Biopharmaceuticals, Inc. (GlobeNewswire, Inc.)] |
|
|
|
|
| November 2 – November 3 Virtual |
|
|
|
|
|
| John Hopkins Medical Institute – Baltimore, Maryland, United States |
|
|
|
| City of Hope – Monrovia, California, United States |
|
|
|
| City of Hope – Duarte, California, United States |
|
|
|
| Weill Cornell Medicine – New York City, New York, United States |
|
|
|
| UT Health – San Antonio, Texas, United States |
|
|
|
|